Estrella Immunopharma is a sub scale clinical stage T cell therapy developer whose entire product story runs through a single related party, and the second quarter print shows the operating engine has largely been switched off. The company ended the period with a quarter end cash balance of $147,000 set against $9.26 million of current liabilities, a gap management has now flagged with a going concern note. The quarter net loss of $2.31 million is narrow, but it is narrow because the spend has been cut, not because the science has advanced.
The strategic tension is that the burn has collapsed on deferred terms from the parent, Eureka. The first half research and development line came almost entirely from that related party, while the only clinical asset, the STARLIGHT-1 trial, remained the sole source of data with two Phase II patients dosed by midyear. The balance sheet is dominated by an accrued milestone payable to the same parent, which sits ahead of the public shareholders on any future value of the program.
The stock now trades near the bottom of its range, around $0.68, on a market cap that the share count places in the low tens of millions. The forward question is whether the equity still carries meaningful option value on EB103, or whether the delisting clock, the going concern note, and the parent tether together cap it at a fraction of any science driven outcome.